XTL Biopharmaceuticals Ltd (XTLB) — Working Capital to Net Assets Ratio
XTL Biopharmaceuticals Ltd (XTLB) has a Working Capital to Net Assets ratio of -16.0% as of December 2024. Working capital of ILA-867.00K (current assets of ILA1.34 Million minus current liabilities of ILA2.21 Million) is measured against net assets of ILA5.43 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See defensive interval ratio of XTL Biopharmaceuticals Ltd to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
XTL Biopharmaceuticals Ltd Working Capital to Net Assets (2013–2024)
This chart shows how XTL Biopharmaceuticals Ltd's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2013 to 2024. As of December 2024, the ratio stands at -16.0%, reflecting working capital of ILA-867.00K against net assets of ILA5.43 Million ILA. For the complete balance sheet picture, see XTL Biopharmaceuticals Ltd (XTLB) total assets.
Annual Working Capital to Net Assets for XTL Biopharmaceuticals Ltd (2013–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for XTL Biopharmaceuticals Ltd from 2013 to 2024, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check XTL Biopharmaceuticals Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (ILA) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -16.0% | ILA-867.00K | ILA5.43 Million | ILA1.34 Million | ILA2.21 Million | ▼ -98.8 pp |
| 2023 | 82.9% | ILA1.84 Million | ILA2.22 Million | ILA2.05 Million | ILA206.00K | ▼ -7.6 pp |
| 2022 | 90.5% | ILA3.62 Million | ILA4.00 Million | ILA3.81 Million | ILA187.00K | ▼ -22.1 pp |
| 2021 | 112.6% | ILA6.01 Million | ILA5.33 Million | ILA6.24 Million | ILA231.00K | ▲ +18.7 pp |
| 2020 | 93.9% | ILA5.87 Million | ILA6.25 Million | ILA6.12 Million | ILA254.00K | ▼ -0.6 pp |
| 2019 | 94.5% | ILA6.60 Million | ILA6.98 Million | ILA6.83 Million | ILA232.00K | ▼ -0.9 pp |
| 2018 | 95.4% | ILA7.94 Million | ILA8.32 Million | ILA8.20 Million | ILA253.00K | ▼ -67.8 pp |
| 2017 | 163.2% | ILA5.91 Million | ILA3.62 Million | ILA6.21 Million | ILA300.00K | ▲ +73.0 pp |
| 2016 | 90.2% | ILA2.42 Million | ILA2.69 Million | ILA2.75 Million | ILA330.00K | ▲ +11.9 pp |
| 2015 | 78.4% | ILA3.83 Million | ILA4.89 Million | ILA4.26 Million | ILA436.00K | ▲ +32.7 pp |
| 2014 | 45.7% | ILA2.14 Million | ILA4.68 Million | ILA3.10 Million | ILA965.00K | ▼ -11.4 pp |
| 2013 | 57.0% | ILA3.87 Million | ILA6.79 Million | ILA5.09 Million | ILA1.22 Million | — |